Announcement of the PerMed Transnational Partnership Call “Cell and Gene Therapy for Personalized Medicine”

The Ministry of Health (hereinafter “MoH”) is publishing onNovember 5, November 5, 2026, in accordance with Act No. 130/2002 Coll., on the Support of Research, Experimental Development, and Innovation from Public Funds and on Amendments to Certain Related Acts (the Act on the Support of Research, Experimental Development, and Innovation), as amended (hereinafter referred to as the “Act”),

transnational partnership call PerMed (European Partnership for Personalized Medicine): “Cell and Gene Therapy for Personalized Medicine” (CGT4PM2027)

Call 2027

Date of announcement of results
, October 2027

National budget allocation for the call
500 000 EUR

Maximum amount of support per project
250 000 EUR

Maximum aid intensity per project
Table: Maximum possible aid intensity by type of entity and type of research (according to the current version Methodology: European Partnerships in Health)

Applicants
nd a research organization, a company, or a patient organization

Project duration
3years / 36 months

Deadlines for submitting project proposals:
Pre-proposals: January 20, 2027, 2:00 p.m. CET
Full proposals: May 25, 2027, 2:00 p.m. CEST

Those interested can participate inan international informational webinar, which will take placeon December 3, 2026 (from 3:00 p.m. to 5:00 p.m. CET). Registration is available at this link: REGISTRATION

Documents

Conditions for the Participation of a Czech Applicant in PerMed CGT4PM2027

Methodology: European Partnerships for Health

Subprogram 3: European Partnerships in Health – effective May 22, 2024

Mandatory attachments of the Czech applicant for Phase 1 (pre-proposals)

Mandatory annexes of the Czech applicant for Phase 2 (full proposals)

Affidavit of competence;
Updated Budget Table(AZV ČR Application Form)

Other documents

Commission Regulation

Frascati Manual

Definition of types of results

The official call documents are available here

Information about the call

The goal of this call for proposals is to fund research projects in the field of human health focused on cell and gene therapy (CGT) within the context of personalized medicine (PM). Projectproposalsmust focus on the development and validation of innovative and novel CGT approaches for PM.

At least one of the following approaches must be used:

Somatic cell therapy;
Gene therapy;
Combined cell and gene therapy;
New biological products, such as mRNA, other nucleic acid-based methods, and extracellular vesicles used as delivery vehicles for gene therapy approaches.

Research projects focusing on all areas of the disease are supported.

Size of the project consortium

Each project consortium must include at least 3 partners from 3 different EU Member States or associated countries whose funding organizations are participating in the call. Each of these partners must be eligible and must apply for funding from the relevant funding organization or agency. All three legal entities must be independent of one another. A maximum of two partners per consortium may apply for funding from the same funding organization or agency. The project coordinator may not be changed between the first and second phases. It is a mandatory requirement that at least one early-career researcher ( ECR) be involved in the consortium in the role of principal investigator (PI).

In project consortia comprising at least three eligible partners for funding, no more than one partner may provide its own funding. A patient organization may be included as a partner. The maximum number of partners in a project consortium is six, and may be increased to seven.

List of participating countries:

Austria (FWF), Belgium (FWO, FIO/VLAIO, F.R.S. – FNRS, SPW EER), Canada (CIHR), the Czech Republic (MZČR/AZVČR), Estonia (EIS, ETAG), Finland (BFRK), France (ANR), Germany (BMFTR/DLR, BMG/DLR, SMWK), Hungary (NKFIH), Ireland (TE-RI), Israel (CSO-MOH, IIA), Italy (IT-MoH, FVG, FRRB, RT), Latvia (LZP), Lithuania (LMT), Luxembourg (FNR), Norway (RCN), Poland (NCBR), Portugal (FCT, VP-GRA), Romania (UEFISCDI), Slovakia (CVTI SR), Spain (CPSEJA, ISCIII, and DS-CAT), Sweden (VINNOVA, SRC), the Netherlands (ZonMw), and Turkey (TÜBITAK).

*The list of participating countries is current as of November 4, 2026.

Call rules:

The call is governed by transnational rules common to applicants from all participating countries. In addition to the transnational rules, Czech applicants must also comply with the national conditions set by the relevant national provider. Applicants participating in applied research projects will therefore have to comply with national conditions based on Sub-programme 3: European Partnerships in Health.

Contact person:

Mgr. Monika Kocmanová
Email:
Tel: +420 778 973 186

You can also submit questions about the transnational call via email: .